Revealing Soon: A Potential Huge Investing Opportunity for Investors
Here is the latest financial fact sheet of CIPLA. For more details, see the CIPLA quarterly results and CIPLA share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 0.5 |
No. of shares | m | 807.45 |
1 Week | % | 5.9 |
1 Month | % | 9.9 |
1 Year | % | 60.9 |
52 week H/L | Rs | 1,519.0/919.8 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
CIPLA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 678 | 586 | 879 | 1,083 | 1,185 | |
Low | Rs | 484 | 357 | 411 | 806 | 852 | |
Sales per share (Unadj.) | Rs | 203.1 | 212.5 | 237.6 | 269.7 | 281.9 | |
Earnings per share (Unadj.) | Rs | 18.7 | 19.2 | 29.8 | 31.7 | 35.1 | |
Diluted earnings per share | Rs | 18.7 | 19.2 | 29.7 | 31.7 | 35.1 | |
Cash flow per share (Unadj.) | Rs | 35.2 | 33.8 | 43.0 | 44.8 | 49.7 | |
Dividends per share (Unadj.) | Rs | 3.00 | 4.00 | 5.00 | 5.00 | 8.50 | |
Adj. dividends per share | Rs | 2.99 | 3.99 | 4.99 | 5.00 | 8.50 | |
Avg Dividend yield | % | 0.5 | 0.8 | 0.8 | 0.5 | 0.8 | |
Book value per share (Unadj.) | Rs | 185.6 | 194.9 | 226.7 | 257.8 | 289.2 | |
Adj. book value per share | Rs | 185.2 | 194.6 | 226.4 | 257.6 | 289.1 | |
Shares outstanding (eoy) | m | 805.70 | 806.24 | 806.46 | 806.81 | 807.15 | |
Price / Sales ratio | x | 2.9 | 2.2 | 2.7 | 3.5 | 3.6 | |
Avg P/E ratio | x | 31.0 | 24.6 | 21.6 | 29.8 | 29.0 | |
P/CF ratio (eoy) | x | 16.5 | 14.0 | 15.0 | 21.1 | 20.5 | |
Price / Book Value ratio | x | 3.1 | 2.4 | 2.8 | 3.7 | 3.5 | |
Dividend payout | % | 16.0 | 20.8 | 16.8 | 15.8 | 24.2 | |
Avg Mkt Cap | Rs m | 468,032 | 379,858 | 519,826 | 762,177 | 822,164 | |
Total wages/salary | Rs m | 28,565 | 30,270 | 32,518 | 35,299 | 38,301 |
CIPLA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 163,624 | 171,320 | 191,596 | 217,633 | 227,531 | |
Other income | Rs m | 4,766 | 3,694 | 2,698 | 3,217 | 5,121 | |
Total revenues | Rs m | 168,390 | 175,014 | 194,294 | 220,851 | 232,653 | |
Gross profit | Rs m | 30,973 | 31,808 | 42,487 | 43,298 | 48,079 | |
Depreciation | Rs m | 13,263 | 11,747 | 10,677 | 10,520 | 11,721 | |
Interest | Rs m | 1,684 | 1,974 | 1,607 | 1,064 | 1,095 | |
Profit before tax | Rs m | 20,791 | 21,782 | 32,901 | 34,933 | 40,384 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 5,695 | 6,312 | 8,888 | 9,338 | 12,029 | |
Profit after tax | Rs m | 15,096 | 15,470 | 24,013 | 25,595 | 28,355 | |
Gross profit margin | % | 18.9 | 18.6 | 22.2 | 19.9 | 21.1 | |
Effective tax rate | % | 27.4 | 29.0 | 27.0 | 26.7 | 29.8 | |
Net profit margin | % | 9.2 | 9.0 | 12.5 | 11.8 | 12.5 |
CIPLA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 124,246 | 117,038 | 131,810 | 147,108 | 168,051 | |
Current liabilities | Rs m | 37,715 | 43,931 | 45,911 | 49,129 | 50,333 | |
Net working cap to sales | % | 52.9 | 42.7 | 44.8 | 45.0 | 51.7 | |
Current ratio | x | 3.3 | 2.7 | 2.9 | 3.0 | 3.3 | |
Inventory Days | Days | 71 | 47 | 65 | 62 | 73 | |
Debtors Days | Days | 9 | 8 | 7 | 6 | 7 | |
Net fixed assets | Rs m | 113,353 | 117,166 | 116,277 | 119,248 | 117,318 | |
Share capital | Rs m | 1,611 | 1,613 | 1,613 | 1,614 | 1,614 | |
"Free" reserves | Rs m | 147,941 | 155,487 | 181,232 | 206,364 | 231,845 | |
Net worth | Rs m | 149,552 | 157,100 | 182,844 | 207,977 | 233,460 | |
Long term debt | Rs m | 38,301 | 23,693 | 12,028 | 4,162 | 0 | |
Total assets | Rs m | 237,619 | 234,228 | 248,372 | 266,523 | 290,067 | |
Interest coverage | x | 13.3 | 12.0 | 21.5 | 33.8 | 37.9 | |
Debt to equity ratio | x | 0.3 | 0.2 | 0.1 | 0 | 0 | |
Sales to assets ratio | x | 0.7 | 0.7 | 0.8 | 0.8 | 0.8 | |
Return on assets | % | 7.1 | 7.4 | 10.3 | 10.0 | 10.2 | |
Return on equity | % | 10.1 | 9.8 | 13.1 | 12.3 | 12.1 | |
Return on capital | % | 12.0 | 13.1 | 17.7 | 17.0 | 17.8 | |
Exports to sales | % | 33.9 | 32.2 | 31.3 | 26.2 | 22.6 | |
Imports to sales | % | 11.6 | 3.4 | 10.9 | 8.2 | 8.9 | |
Exports (fob) | Rs m | 55,419 | 55,175 | 59,951 | 57,094 | 51,516 | |
Imports (cif) | Rs m | 19,041 | 5,903 | 20,911 | 17,803 | 20,202 | |
Fx inflow | Rs m | 57,410 | 56,036 | 68,051 | 60,180 | 64,282 | |
Fx outflow | Rs m | 19,041 | 5,903 | 20,911 | 17,803 | 20,202 | |
Net fx | Rs m | 38,368 | 50,133 | 47,140 | 42,376 | 44,080 |
CIPLA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 16,911 | 30,685 | 37,552 | 33,259 | 32,377 | |
From Investments | Rs m | -16,687 | 1,040 | -23,872 | -18,719 | -23,885 | |
From Financial Activity | Rs m | -3,487 | -29,488 | -12,395 | -15,998 | -9,583 | |
Net Cashflow | Rs m | -3,451 | 2,340 | 1,413 | -1,323 | -968 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Y K Hamied | COMP SEC: Rajendra Chopra | YEAR OF INC: 1935 | BSE CODE: 500087 | FV (Rs): 2 | DIV YIELD (%): 0.6 |
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB SUN PHARMA ZYDUS LIFESCIENCES MANKIND PHARMA
Compare CIPLA With: DIVIS LABORATORIES DR. REDDYS LAB SUN PHARMA ZYDUS LIFESCIENCES MANKIND PHARMA
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended on firm footing.